130 W 8th Street
Suite 208
Erie, PA 16501 Strength through Innovation
Fortitude Group Inc., (FGI) develops practical solutions for healthcare with direct holdings, subsidiaries and or joint ventures. The Company's service-product portfolio includes premium FDA approved medical devices and advanced technologies engineered to prevent the risk associated healthcare acquired conditions and improve clinical outcomes.
Fortitude Group Inc., which trades under the ticker symbol FRTD, is a diversified holding company seeking to enhance shareholder value via quality acquisitions, joint ventures and strategic partnerships.
FGI is headquartered in Erie Pennsylvania, in the heart of Erie's technology incubator center. This dynamic company is positioned to capitalize in various diverse market places.
Through its direct holdings, subsidiaries and and/or joint ventures the Fortitude Group Inc. Life Science Division will provide the healthcare market with premium products including innovative medical devices, advanced medical technologies and protocol procedures engineered to prevent the risk of infection in the peri-operative setting and improve clinical healthcare outcomes for patients and providers.
About: Fortitude Group Inc.
Vision Statement
Fortitude Group Inc., immediate focus is to concentrate in developing our Life Science Division. It is within this division that management strongly believes that shareholder value will be recognized quickly. FGI is committed to provide a suitable return in all our business endeavors that will allow growth and sustainability. The FGI Life Science Division develops practical solutions for healthcare with direct holdings, subsidiaries and or joint ventures. The Company's service-product portfolio includes premium FDA approved medical devices and advanced technologies engineered to prevent the risk associated with (HAC) healthcare acquired conditions with the goal of improving clinical outcomes. With future products, services and medical devices opportunities contained within a pipeline thus positioning the company to achieve a generous percentage of market share from an industry segment that is rapidly expanding.
Mission Statement
Our mission is to set standards of excellence for providing medical devices and services from within our Life Science Division to the healthcare industry. Our company's success, which is characterized by responsiveness and clinical excellence, has been founded on our core principle of dedication and quality care. Physicians, care givers and patients alike can trust FGI's Life Science Division to provide the quality products and services needed to achieve the care they expect and deserve.
Thomas Parilla - Chief Executive Officer:
CEO and Chairman of the Board of Publicly traded Fortitude Group Inc. Mr Parilla is charged with leading Fortitude Group Inc. through its growth stage, and assisting the company in locating and closing quality acquisitions. Providing the company with both growth potential, and the ability to attract proper funding to strengthen its balance sheet
Mr. Thomas Parilla is a graduate from Mercyhurst University, in Erie, PA having earned his BA Economics. He has 20 years of international and domestic blue chip experience, in both the retail brokerage and investment banking sectors. Mr. Parilla's ties to the university remain close to this day. He currently serves on its Board of Trustees Investment Committee.
He has been featured multiple times in magazines, and also was the economics expert featured on a CBS morning segment entitled "Ask the Experts". Born and raised in the small steel and coal town of Mineral Ridge, Ohio, Mr. Parilla learned the value of a strong work ethic at an early age.
Christopher Cuzzola - President - CEO Life Science Division:
Christopher J. Cuzzola received a M.Ed. in Administrative Leadership, Learning Theory, and Design from Edinboro University and a B.A. from Mercyhurst University. Cuzzola brings a history of exceptional performance applying his entrepreneurial skills to the challenging life science medical device industry.
During his career with Pfizer, Chris was a consistent high achiever while earning several top specialty and hospital sales performance awards, including a number one ranking as national sales representative of the year. Cuzzola has extensive training in various disease states including infectious diseases. In addition to family and professional passions, Chris remains dedicated to causes associated with advancing education and research.
Anthony J. Colantonio, MD - Chief Medical Innovation Officer
Dr. Colantonio completed fellowship training in Interventional Pain Medicine at the Oregon Health and Science University, residency training at Duke University in Anesthesiology, and medical and undergraduate education at Georgetown University and is a Diplomat of the American Board of Anesthesiology and the American Academy of Pain Management.
Dr. Colantonio is the Director of the Clinic for Specialty Pain Services at Meadville Medical Center, with a clinical focus upon neuromodulation therapy and geriatric care. Dr. Colantonio is a regional key opinion leader for numerous pharmaceutical and medical device companies and a national speaker for Pfizer Pharmaceuticals.
As the Chief Medical Officer of the Life Science Division, Dr. Colantonio leads the research and development efforts from initial product design to bench-top testing, clinical trials, and final product validation through the company's regulatory and quality efforts.
On January 29, 2013 - Fortitude Group Inc., announced the acquisition of Legacy Life Science (L2S)
The L2S premium product portfolio contains the Comprehensive Airway Management System consisting of five, patented FDA approved products ready for worldwide distribution and sales. The Comprehensive Airway Management System is engineered to significantly reduce and prevent respiratory distress in the perioperative procedural sedation environment (anesthesia). A common scenario in peri-operative procedural sedation involves degradation of patient airway monitoring and management; and therefore, constitutes the designation as a Hospital Acquired Condition or (HAC) for respiratory related distress.
The L2S Comprehensive Airway Management System meets the new ASA Standards.
Every year thousands of patients suffer harm or die from health care acquired infections (HCAI). It is estimated that 30% of HCAI's are preventable. Due to the invasive nature of clinical procedures, health care workers are inherently a significant vector of infection. Of course, health care professionals do not set out to harm patients during clinical procedures, quite the contrary. But the risk that health care professionals pose must be acknowledged and minimized as much as is practically possible.
Eighty percent of complications during anesthesia are due to airway mishaps and respiratory distress (i.e., obstruction and/or closure). A recent market designation of capnography as a "standard of care" by the American Society of Anesthesiologists (ASA) and other professional organizations clearly recognize the growing importance to protect patients from respiratory events leading to death, these respiratory events are categorized as HAC(s).
Annually there are 1M pulmonary complications after surgical procedures, 350,000 respiratory arrests and over 46,000 deaths in the U.S. Resulting in 3M added patient days, with 2M added to the ICU which adds over $12 billion to the cost of health care.
With innovative capnography cannulas and superior airway monitoring products, the Life Science Division of Fortitude Group Inc., can provide comfort and safety to all patients in all environments.
Fortitudes Group Inc., Life Science Division's Capnography meets the needs of both the practitioner and the patient in all clinical environments by providing the earliest indication of airway obstruction and cessation of breathing. With our products, the caregiver is given instantaneous, continuous results, and is able to intervene at the earliest sign of distress.
Share Structure:
Shares Outstanding- 484,634,404 a/o Jan 24, 2013
Float- 131,915,067 a/o Jan 24, 2013
Authorized Shares- 998,000,000 a/o Jan 23, 2013
Par Value 0.001
Shareholders of Record -267 a/o Jan 24, 2013
Company Headlines
February 11, 2013 - Fortitude Group Inc., updates shareholders of material events.
Jan 29, 2013 - Fortitude Group Inc., CEO Thomas Parilla today introduces its first acquisition to its medical division, Legacy Life Science (L2S).
January 28, 2013 - Fortitude Group Inc., Introduces Anthony J. Colantonio, MD Chief Medical Innovation Officer of the Life Science Division.
January 25, 2013 - Fortitude Group Inc.,Introduces Christopher J. Cuzzola as President.
January 24, 2013 - Fortitude Group Inc. Announces the Promotion of Thomas Parilla to the Position of CEO
130 W 8th Street
Suite 208
Erie, PA 16501
Strength through Innovation
Fortitude Group Inc., (FGI) develops practical solutions for healthcare with direct holdings, subsidiaries and or joint ventures. The Company's service-product portfolio includes premium FDA approved medical devices and advanced technologies engineered to prevent the risk associated healthcare acquired conditions and improve clinical outcomes.
Fortitude Group Inc., which trades under the ticker symbol FRTD, is a diversified holding company seeking to enhance shareholder value via quality acquisitions, joint ventures and strategic partnerships.
FGI is headquartered in Erie Pennsylvania, in the heart of Erie's technology incubator center. This dynamic company is positioned to capitalize in various diverse market places.
Through its direct holdings, subsidiaries and and/or joint ventures the Fortitude Group Inc. Life Science Division will provide the healthcare market with premium products including innovative medical devices, advanced medical technologies and protocol procedures engineered to prevent the risk of infection in the peri-operative setting and improve clinical healthcare outcomes for patients and providers.
About: Fortitude Group Inc.
Vision Statement
Fortitude Group Inc., immediate focus is to concentrate in developing our Life Science Division. It is within this division that management strongly believes that shareholder value will be recognized quickly. FGI is committed to provide a suitable return in all our business endeavors that will allow growth and sustainability. The FGI Life Science Division develops practical solutions for healthcare with direct holdings, subsidiaries and or joint ventures. The Company's service-product portfolio includes premium FDA approved medical devices and advanced technologies engineered to prevent the risk associated with (HAC) healthcare acquired conditions with the goal of improving clinical outcomes. With future products, services and medical devices opportunities contained within a pipeline thus positioning the company to achieve a generous percentage of market share from an industry segment that is rapidly expanding.
